Skip to main content
SpringerLink
Log in

Brolucizumab: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Brolucizumab (Beovu®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular oedema secondary to retinal vein occlusion. Based primarily on the results of the phase III HAWK and HARRIER trials brolucizumab was recently approved in the US for the treatment of wet AMD. This article summarizes the milestones in the development of brolucizumab leading to this first approval.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Novartis. BEOVU® (brolucizumab-dbll) injection, for intravitreal injection: US prescribing information. 2019. https://www.pharma.us.novartis.com/sites/, www.pharma.us.novartis.com/files/beovu.pdf. Accessed 11 Nov 2019.

  2. Novartis. Novartis receives FDA approval for BEOVU®, offering wet AMD patients vision gains and greater fluid reductions vs aflibercept [media release]. 8 Oct 2019. https://www.prnewswire.com.

  3. Alcon. Alcon to acquire Swiss biotechnology firm, ESBATech AG [media release]. 14 Sep 2009. http://www.alcon.com.

  4. Alcon. Alcon and Novartis complete merger and form new Alcon Division to accelerate global leadership in eye care [media release]. 8 Apr 2011. http://www.alcon.com.

  5. Novartis. Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off [media release]. 9 Apr 2019. http://www.novartis.com.

  6. Gaudreault J, Gunde T, Floyd HS, et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53(14):3025.

    Google Scholar 

  7. Tietz J, Spohn G, Schmid G, et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders [abstract]. Invest Ophthalmol Vis Sci. 2015;56(7):1501.

    Google Scholar 

  8. Holz FG, Dugel PU, Weissgerber G, et al. Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study. Ophthalmology. 2016;123(5):1080–9.

    Article  Google Scholar 

  9. Nimz EL, Van TLCW, Yanez JA, et al. Intraocular and systemic pharmacokinetics of brolucizumab (RTH258) in nonhuman primates [abstract]. Invest Ophthalmol Vis Sci. 2016;57(12):4996.

    Google Scholar 

  10. Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2019. https://doi.org/10.1016/j.ophtha.2019.04.017.

    Article  PubMed  Google Scholar 

  11. Singh RP, Wykoff CC, Tadayoni R, et al. Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci. 2019;60(9):5194.

    Google Scholar 

  12. Dugel PU, Lang GE, Razavi S, et al. Predictability of the 12-week dosing status at week 48 for patients receiving brolucizumab in HAWK and HARRIER [abstract]. Investig Ophthalm Vis Sci Conf. 2018;59(9):1455.

    Google Scholar 

  13. Dugel PU, Jaffe GJ, Sallstig P, et al. Brolucizumab versus aflibercept in participants with neovascular age-related macular degeneration: a randomized trial. Ophthalmology. 2017;124(9):1296–304.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Anthony Markham

Authors
  1. Anthony Markham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anthony Markham.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.

Additional information

Enhanced material for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.10317539.

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Markham, A. Brolucizumab: First Approval. Drugs 79, 1997–2000 (2019). https://doi.org/10.1007/s40265-019-01231-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-019-01231-9

Search

Navigation